Continuous Coverage and Clinical Application of Real-Time CGM:
Pathway to Improved Outcomes and Reduced Cost with Kathleen Wyne, MD, PhD, and Eric A. Orzeck, MD
This activity is available for CME credit. To receive credit, please register and take the pretest below.
Kathleen Wyne, MD, PhD, FACE, FNLA
Associate Professor of Clinical Medicine
Division of Endocrinology, Diabetes and Metabolism, College of Medicine
The Ohio State University Wexner Medical Center
Eric A. Orzeck, MD, FACP, FACE
Endocrinologists and other healthcare professionals who assess, diagnose, and treat patients with diabetes
Statement of Need
Self-monitoring of blood glucose is a core component of a diabetic patient's management but only provides a measurement of blood glucose levels at a specific point in time, without necessarily informing about trends and hyperglycemic or hypoglycemic excursions. Glycosylated hemoglobin (A1C) is an even more limited measure, as it reports a mean of readings over 90 days; therefore, the patient is not alerted about fluctuations in blood glucose at any point in time.
Selection of an appropriate continuous glucose monitoring (CGM) device is important because improvements in accuracy and reliability are ongoing. Real-time (RT) CGM is one cornerstone of optimal glycemic control. Each CGM device varies; relying on different sensing technology and requiring the traditional finger-sticks for confirmation of alerts. The mean absolute relative difference (MARD) between sensor readings and reference glucose levels can vary by as much as 20%, with worrisome discrepancies in the hypoglycemic range. However, new-generation devices have significantly improved MARD measurements. These devices have shorter lag times and greater accuracy.
Many physicians lack the appropriate level of knowledge to employ CGM as part of their practices, highlighting the need for staff training and programs for patient training. Furthermore, economic data support reimbursement benefits of CGM, underscoring recent efforts to expand coverage. Educational programs focused on these knowledge and coverage gaps will enable healthcare professionals to provide improved patient care and continuous coverage to improve healthcare outcomes.
At the conclusion of this activity, participants should be better able to:
- Understand how patients living with diabetes use their continuous glucose monitoring (CGM) device to make management decisions
- Identify methods for optimization of therapy and improve clinical outcomes using real-time (RT) personal and professional CGM in both adult and pediatric populations
- Assess economic data that support reimbursement benefits of CGM, underscoring recent efforts to expand coverage
Accreditation and Certification
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Dannemiller and CogniMed Inc. Dannemiller is accredited by the ACCME to provide continuing medical education for physicians.
Dannemiller designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
There is no fee to participate in this activity.
Content Review Statement
To resolve identified/potential conflicts of interest, the education content was fully reviewed by a physician member of the Dannemiller Clinical Content Review Committee who have no financial relationships with commercial interests. The resulting certified activity was found to provide educational content that is current, evidence based and commercially balanced.
It is the policy of Dannemiller to ensure fair balance, independence, objectivity, and scientific rigor in all programming. All faculty participating in sponsored programs are expected to identify and reference off-label product use and disclose any significant relationships with those supporting the activity or any others whose products or services are discussed. The faculty for this activity have disclosed that there will be discussion about the use of products for non-FDA-approved indications. In accordance with the Accreditation Council for Continuing Medical Education standards, parallel documents from other accrediting bodies, and Dannemiller policy, the following disclosures have been made:
Bernard Abrams, MD, Clinical Content Reviewer, has nothing to disclose.
Gordon Ringler, Assistant Director, Medical Education, has nothing to disclose.
CogniMed Inc. Staff
Estelle Perera, Senior Director, Scientific Affairs and Program Design, has nothing to disclose.
Kathleen Wyne, MD, PhD, is a speaker for Novo Nordisk, Astra Zeneca, Salix and GlaxoSmithKline.
Eric A. Orzeck, MD, is a speaker for Novo Nordisk and Astra Zeneca.
The ideas and opinions presented in this educational activity are those of the faculty and do not necessarily reflect the views of Dannemiller and/or its agents. As in all educational activities, we encourage the practitioners to use their own judgment in treating and addressing the needs of each individual patient, taking into account that patient's unique clinical situation. Dannemiller disclaims all liability and cannot be held responsible for any problems that may arise from participating in this activity or following treatment recommendations presented.
This activity is supported by an independent educational grant provided by Dexcom.
This activity is an enduring program and consists of an audio recording and slide presentation. Successful completion is achieved by listening to the audio and viewing the slide presentation, reflecting on the content's implications in your practice, and completing the assessment component.
The estimated time to complete this activity is 1.0 hour.
To receive credit for this activity, participants must complete the posttest with a passing score of 80% and then complete the evaluation.
This activity was originally released July 24, 2015, and is eligible for credit through July 24, 2016.
CME Registration and Pretest
Please enter your email below and provide missing (*) information. Then please take the Pretest below.
1. Findings of the Centers for Disease Control and Prevention show that hypoglycemia from antidiabetic medications is the _______ cause of emergency department visits and hospitalizations due to adverse drug reactions in the United States.
2. The key benefit(s) of continuous glucose monitoring (CGM) to the patient is/are
3. Which of the following statement(s) about CGM is/are true?
4. Professional CGM can be billed no more than every _______ days
5. Currently, costs for a hypoglycemia inpatient admission average ______ per event.
6. Professional real-time CGM provides dynamic and comprehensive data collection to show patients and clinicians
Thank you for registering. You will, or may have already received, the links for this webcast in a confirmation email. Please contact us if you have any questions.
© 2015 CogniMed Inc. All rights reserved. CGM17002a July 2015